drugset / Trial / NCT06097728
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Timeline
- Start
- 2023-11-09
- Primary completion
- 2028-11-16
- Completion
- 2028-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Comparator | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |